Ed Lukins

Partner

Лондон

Ed counsels public and pre-IPO private companies, investors, entrepreneurs and underwriters on UK capital markets transactions, as well as on primary and secondary listings on Nasdaq and NYSE by UK and European companies.

Ed has advised companies on listings on AIM and the Main Market, and a large number of non-US companies (both domestic and foreign private issuers) on US IPOs, direct listings and follow-on offerings. He also advises on general corporate finance and securities regulatory matters for listed issuers (including the listing rules, MAR and the Takeover Code).

His broad industry experience includes working with companies in the energy, financial services, healthcare and life sciences, retail, media, natural resources and technology sectors.

  • Ed's experience include advising:

    • Kistos plc, a SPAC focused on energy, on its AIM IPO and subsequent reverse takeover of Tulip, associated placing, PrimaryBid offer, subscription and Norwegian listed bond offering
    • National World plc, a SPAC focused on news publishing, on its Main Market IPO and Standard listing, and acquisition of JPI Media
    • Tiziana Life Sciences plc, a clinical-stage biopharmaceutical company, on its Nasdaq dual-listing and global follow-on offerings, and spin-out of Accustem Sciences Limited
    • Endava plc, a software development company, on its NYSE IPO Realm Therapeutics plc, a clinical-stage biopharmaceutical company, on its direct dual-listing on Nasdaq, subsequent AIM delisting and acquisition by Essa Pharma Inc. by way of scheme of arrangement
    • OKYO Pharma Limited, a pre-clinical biopharmaceutical company, on its Main Market IPO and Standard listing
    • Panther Metals plc, a mineral exploration company, on its Main Market IPO and Standard listing
    • One Media iP Group plc, a digital music rights acquirer, publisher and distributor, on a Main Market placing
    • MightyHive Inc., a data and digital media consultancy, on its acquisition by S4 Capital plc, a digital advertising/marketing company
    • Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, on its demerger and AIM IPO
    • Cobra Resources plc, a mineral exploration company, on its Main Market IPO and Standard listing
    • MetalNRG, a mineral exploration company, on its Main Market IPO and Standard listing
    • Castillo Copper Limited, an ASX-listed mineral exploration company, on its Main Market IPO and Standard listing
    • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, on its Nasdaq IPO and follow-on securities offerings
    • the placing agent on a Main Market placing for Nuformix, a clinical-stage pharmaceutical company
    • RockRose Energy plc, a SPAC focused on existing oil and gas producing assets, on its Main Market IPO and Standard listing, two reverse takeovers (North Sea asset acquisitions) and a recommended cash offer by Viaro Energy
    • Scancell Holdings plc, a clinical-stage biopharmaceutical company, on various AIM follow-on securities offerings
    • the underwriters on the Nasdaq IPO of Bicycle Therapeutics plc, a biopharmaceutical company
    • the underwriters on the Nasdaq IPO and various follow-on offerings for NuCana plc, a biopharmaceutical company
    • the underwriters on the aborted Nasdaq IPO of Kymab Limited, a clinical-stage biopharmaceutical company
    • the underwriters on the aborted Nasdaq IPO of Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company
    • the underwriters on the aborted Nasdaq IPO of Verona Pharma plc, a clinical-stage biopharmaceutical company
    • Local World Limited on its sale to Trinity Mirror plc (now Reach plc)

    Please note: Ed's experience includes that prior to joining Orrick.